Citi: Tigermed (300347.SZ/3347.HK): Leading China Clinical CRO; Rebound Likely Underway
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
Citi designates Tigermed as its top industry pick, asserting that recent project price recoveries signal a broader sector rebound. The bank expects order momentum to strengthen throughout 2026, bolstered by improving financing conditions for innovative drugs. Following three years of intense price competition, Tigermed is well-positioned to initiate price increases in early 2026, directly benefiting from rising client demand.
Citi projects an acceleration in top-line growth to double digits for 2026, supported by robust backlog growth and expanding margins. The company's investment income during favorable bull markets could also drive significant earnings outperformance. Over the long term, government support for innovative drugs, an influx of overseas biotechs conducting clinical trials in China, strategic cross-border mergers and acquisitions, and artificial intelligence-driven operational efficiencies serve as strong tailwinds.
Although consensus expectations model only a low double-digit revenue increase for 2026, Citi argues that management's current guidance remains conservative. The bank highlights substantial upside potential, forecasting a 44% year-over-year increase in operating profit for 2026 as legacy projects are cleared. Tigermed held the leading position in China's clinical contract research organization (CRO) market in 2023, commanding a 12.8% revenue share. Furthermore, the company has serviced 60% of all Class 1 innovative drugs in China over the past two decades.
Citi maintains a Buy rating on Tigermed. The A-share (300347.SZ) target price is set at RMB 67.00, based on a sum-of-the-parts (SOTP) valuation. The H-share (3347.HK) target price is established at HKD 73.00. Key downside risks include softer-than-expected orders, intensified market competition, underwhelming investment yields, and short-term margin pressures from artificial intelligence investments.